There has been a major change in the senior management of Guangyao Baiyunshan.
On the evening of July 22, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. issued an announcement, saying that the company's board of directors received a written resignation report submitted by Li Chuyuan, chairman of the company, on the same day. After his resignation, Li Chuyuan no longer held any position in the company.
According to public information, Li Chuyuan joined the work in July 1988 and has successively worked in Guangzhou Baiyunshan Pharmaceutical General Factory, Guangzhou Baiyunshan Pharmaceutical Co., Ltd., Guangzhou Baiyunshan Traditional Chinese Medicine Factory, Guangzhou Baiyunshan Hutchison Whampoa Traditional Chinese Medicine Co., Ltd., Guangzhou Pharmaceutical Group Co., Ltd. (hereinafter referred to as Guangzhou Pharmaceutical Group) and many other companies.
Among them, Li Chuyuan has been the vice chairman of Baiyunshan since June 28, 2010, and the chairman of Baiyunshan since August 8, 2013, and so far, Li Chuyuan has been at the helm of Baiyunshan for nearly 11 years.
Li Chuyuan's sudden resignation did not cause the number of members of Baiyunshan's board of directors to fall below the legal minimum, but someone still needs to perform the duties of chairman on his behalf.
On July 22, the twelfth meeting of the ninth board of directors of Baiyunshan deliberated and agreed that Yang Jun, its vice chairman, would perform the duties of the chairman on his behalf, and the period would be from the date of approval of the board of directors to the date of election of the new chairman of the board of directors.
The industry is in the window period of transformation and upgrading
Under the helm of Li Chuyuan, Baiyunshan focuses on the pharmaceutical and health industry, and is known as the leader of the pharmaceutical industry in South China with the integration of industry and commerce, and is currently mainly engaged in four major business segments.
From the point of view of single products, sildenafil citrate tablets and Wanglaoji herbal tea, which are known as "domestic viagra", are a strong driving force for Baiyunshan's performance.
Among them, Wanglaoji, a well-known herbal tea brand, is owned by Guangzhou Wanglaoji Pharmaceutical Co., Ltd., a subsidiary of Baiyunshan.
However, the pharmaceutical industry in which Baiyunshan is located is still in an important window period of transformation and upgrading.
On the one hand, the pharmaceutical industry is facing challenges such as consistency evaluation, centralized drug procurement, rising raw material prices, and medical insurance payment. On the other hand, the successive introduction of policies such as the revitalization and development of traditional Chinese medicine, the guidance of drug research and development and imitation, and medical services will effectively stimulate the innovation and creativity of pharmaceutical enterprises.
In the first quarter of 2023 and 2024, Baiyunshan will achieve net profit attributable to the parent company of 4.056 billion yuan and 1.958 billion yuan respectively, a year-on-year increase of 2.25% and 2.59% respectively.
Baiyunshan introduced in the 2023 annual report that during the reporting period, affected by factors such as drug price reductions and raw material price increases, the main economic indicators of the pharmaceutical industry were in a downward trend, and the operation trend of various sub-industries continued to diverge.
As of the close of trading on July 22, the total market value of Baiyunshan was 50.37 billion yuan.
Source: China Fund News, Southern Metropolis Daily, The Paper, etc
Editor: Tang Wei
Review: Zhong Ling
Final review: Peng Deguang